Cellm

Cellm is a South Korean biotechnology company specializing in the development of next-generation cell therapies using induced pluripotent stem cells (iPSCs). The company focuses on addressing neurodegenerative disorders, with a primary emphasis on Parkinson's disease through the replacement of damaged dopaminergic neurons. By leveraging its proprietary differentiation and mass-production technologies, Cellm aims to provide standardized, high-purity cell products that overcome the limitations of traditional donor-derived therapies. The company is currently advancing its lead programs through pre-clinical validation to establish a robust pipeline for central nervous system diseases.